Related Experiment Videos
Tpl-2/Cot and COX-2 in breast cancer
Zuzana Krcova1, Jiri Ehrmann, Veronika Krejci
1Laboratory of Molecular Pathology, Department of Pathology, Faculty of Medicine and Dentistry, Palacky University, University Hospital, Olomouc, Czech Republic. krcova.zuzana@seznam.cz
Summary
New research highlights Tumor Progression Locus 2 (Tpl2/Cot) and Cyclo-oxygenase 2 (COX-2) as potential prognostic factors for breast cancer. These molecules may offer new insights into predicting breast cancer progression and treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Breast cancer incidence is rising globally, necessitating novel prognostic and predictive factors beyond established markers.
- Current breast cancer management relies on histological type, grade, stage, and biomarker status, but improved prediction is needed.
Purpose of the Study:
- To review and summarize current knowledge on Tpl2/Cot and COX-2 as potential prognostic and predictive factors in breast cancer.
- To explore the roles of Tpl2/Cot and COX-2 in intracellular signaling pathways relevant to cancer development.
Main Methods:
- Minireview of existing literature on Tpl2/Cot and COX-2 in breast cancer.
- Analysis of Tpl2/Cot and COX-2 involvement in cellular signaling pathways.
Main Results:
- Tpl2/Cot, a serine/threonine protein kinase, is upregulated in 40% of breast cancers, activating key signaling pathways (ERK1/2, JNK, NF-kappaB, p38MAPK).
- Cyclo-oxygenase 2 (COX-2) expression in breast cancer varies widely (5-100%) and is higher in poorly differentiated tumors.
- Both Tpl2/Cot and COX-2 are implicated in distinct intracellular pathways contributing to tumorigenesis.
Conclusions:
- Tpl2/Cot and COX-2 show promise as novel prognostic and predictive biomarkers for breast cancer.
- Further research is warranted to validate the clinical utility of Tpl2/Cot and COX-2 in breast cancer management.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...